Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive prostate cancer
ORION CORPORATION PRESS RELEASE17 FEBRUARY 2022 at 23.32 EET Darolutamide plus androgen deprivation therapy and docetaxel…